Long-term survival analysis in metastatic melanoma: Serum S100B is an independent prognostic marker and superior to LDH

Onkologie

Volumn 31, Issue 7, 2008, Pages 380-384

  Egberts, Friederike ^a   Pollex, Andrea ^a   Egberts, Jan Hendrik ^a   Kaehler, Katharina C ^a   Weichenthal, Michael ^a   Hauschild, Axel ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Long term survival; Metastatic melanoma; Prognostic factors; S100B; Tumor markers

Indexed keywords

LACTATE DEHYDROGENASE; PROTEIN S100B;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; METASTASIS; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GERMANY; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SKIN NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 47049131220     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000135492     Document Type: Article

References (19)

1. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A: Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001;19:3622-3634.
2. Eigentler TK, Caroli UM, Radny P, Garbe C: Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-759.
3. Brochez L, Naeyaert JM: Serological markers for melanoma. Br J Dermatol 2000;143:256-268.
4. Finck SJ, Giuliano AE, Morton DL: LDH and melanoma. Cancer 1983;51:840-843.
5. Deichmann M, Benner A, Bock M, Jackel A, Uhl K, Waldmann V, Naher H: S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999;17:1891-1896.
6. Donato R: Perspectives in S-100 protein biology. Review article. Cell Calcium 1991;12:713-726.
7. Hauschild A, Michaelsen J, Brenner W, Rudolph P, Glaser R, Henze E, Christophers E: Prognostic significance of serum S100B detection compared with routine blood parameters in advanced metastatic melanoma patients. Melanoma Res 1999;9:155-161.
8. Hauschild A, Engel G, Brenner W, Glaser R, Monig H, Henze E, Christophers E: Predictive value of serum S100B for monitoring patients with metastatic melanoma during chemotherapy and/or imunotherapy. Br J Dermatol 1999;140:1065-1071.
9. Kaskel P, Berking C, Sander S, Volkenandt M, Peter RU, Krahn G: S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma. J Am Acad Dermatol 1999;41:962-969.
10. Henze G, Dummer R, Joller-Jemelka HI, Boni R, Burg G: Serum S100 - a marker for disease monitoring in metastatic melanoma. Dermatology 1997;194:208-212.
11. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, Schittek B: Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription- polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer 2003;97:1737-1745.
12. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A Jr, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF: Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-3648.
13. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA: A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978;188:732-742.
14. Neuber K, Eidam B. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival. Onkologie 2006;29:361-365.
15. Banfalvi T, Boldizsar M, Gergye M, Gilde K, Kremmer T, Otto S: Comparison of prognostic significance of serum 5-S-cysteinyldopa, LDH and S-100B protein in stage III-IV malignant melanoma. Pathol Oncol Res 2002;8:183-187.
16. Krahn G, Kaskel P, Sander S, Waizenhofer PJ, Wortmann S, Leiter U, Peter RU: S100 beta is a more reliable tumor marker in peripheral blood for patients with newly occurred melanoma metastases compared with MIA, albumin and lactate-dehydrogenase. Anticancer Res 2001;21:1311-1316.
17. Schmitz C, Brenner W, Henze E, Christophers E, Hauschild A: Comparative study on the clinical use of protein S-100B and MIA (melanoma inhibitory activity) in melanoma patients. Anticancer Res 2000;20:5059-5063.
18. Brand CU, Ellwanger U, Stroebel W, Meier F, Schlagenhauff B, Rassner G, Garbe C: Prolonged survival of 2 years or longer for patients with disseminated melanoma. An analysis of related prognostic factors. Cancer 1997;79:2345-2353.
19. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS: Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998;16:1103-1111.